Global News

TraceLink releases automated validation manager

Tuesday, June 6, 2017

TraceLink, a Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, announced Automated Validation Manager (AVM)—a web-based offering that automates the entire validation lifecycle of the TraceLink Life Sciences Cloud on an ongoing basis.

[Read More]

Certara launches CODEx

Tuesday, June 6, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.

[Read More]

Hassman Research Institute appoints Dr. Larry Ereshefsky CSO, Early Phase Development

Tuesday, June 6, 2017

Hassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and advancing the company’s Early Phase Development Division focusing on diseases. He will report to Dr. Howard Hassman, CSO of HRI.

[Read More]

Study: New class of oncology therapies provides more options, better outcomes

Monday, June 5, 2017

During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer, according to new research from the QuintilesIMS Institute. Since 2011, 68 novel therapies have been approved across 22 cancer indications globally. These developments have led to more options as well as greater access and improved outcomes for patients—especially for those individuals with metastatic disease.

[Read More]